ECO Animal Health

What ECO Animal Health does

ECO Animal Health Group plc is a UK-headquartered, AIM-listed veterinary pharmaceuticals company that develops, registers and markets branded pharmaceuticals for pigs and poultry. Founded in 1972 and refocused exclusively on animal health from 2007, the company sells prescription-only medicines through a hybrid distribution model spanning subsidiaries in eight countries, joint ventures in China and the US/Canada, and third-party distributors across more than 70 countries.

The company's technology platform centres on Aivlosin®/Valosin® — a proprietary, patented next-generation macrolide antibiotic containing tylvalosin effective against respiratory and enteric diseases — alongside the Ecomectin® parasiticide range and an emerging vaccine family branded ECOVAXXIN®. ECOVAXXIN® MS (Mycoplasma synoviae vaccine) received EU marketing authorisation in December 2025 and is launching commercially across Europe in 2026–2027; ECOVAXXIN® MG (Mycoplasma gallisepticum) received a favourable USDA safety assessment in March 2026. A pipeline including long-acting Florfenicol and vaccines for MDV, IBDV, NDV, ILTV, IBV and PRRSV is under development, primarily through partnerships with Imperial College London, Moredun Research Institute and other research institutions.

The business model is prescription pharmaceutical distribution through veterinary channels, with no public pricing disclosure and revenue generated via one-time product sales. Customers are pig and poultry producers (including major integrators reached via key account management), with EU strategic distribution partners signed in 2026 providing access to over 220 million layer birds annually. The company is profitable and employs over 200 staff across seven offices, with its lead brand Aivlosin® ranked among the Top 30 global animal health brands and Top 10 livestock brands.

Name

ECO Animal Health

Legal name

ECO Animal Health Group plc

Website

https://ecoanimalhealth.com

Company type

Public

Founded year

1972

Operating status

Operating

Headcount range

101–250 employees

Short description

ECO Animal Health is a UK-headquartered, AIM-listed veterinary pharmaceutical company developing and marketing branded antibiotics (Aivlosin®) and vaccines (ECOVAXXIN®) for pigs and poultry across 70+ countries through subsidiaries, joint ventures, and distribution partners.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals (Animal Health)

NAICS

Veterinary Services (541940), Veterinary Services (54194)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB)

akta.pro secondary industries

Antimicrobials & Anti-infectives (HLAMAEAE), Veterinary Vaccines (Biologics) (HLAMAEAL), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)

Keywords

• Veterinary pharmaceuticals
• Animal health products
• Livestock vaccines
• Pig antibiotics
• Poultry medicines

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Veterinary Pharmaceuticals Sales: Sale of branded veterinary pharmaceutical products for pigs and poultry including Aivlosin®/Valosin®, Ecomectin® products, and other generic medications. Products sold through prescription-only veterinary channels.
2. Vaccine Product Sales: Sale of proprietary vaccines including ECOVAXXIN® MS and future vaccine products from R&D pipeline. Commercial launch beginning 2026.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

ECO Animal Health develops, registers and markets branded proprietary veterinary pharmaceuticals for pigs and poultry globally. Its core product is Aivlosin®/Valosin®, a patented macrolide antibiotic (tylvalosin) effective against respiratory and enteric diseases, complemented by the ECOVAXXIN® vaccine family (MS and MG targeting Mycoplasma synoviae and gallisepticum) and Ecomectin® parasiticides.

Product overview

ECO Animal Health is a pharmaceutical company that develops and markets branded veterinary pharmaceuticals globally, focused on antibiotics and vaccines for pigs and poultry. The core product is Aivlosin®/Valosin®, a proprietary patented macrolide antibiotic for respiratory and enteric diseases. The company is expanding into biologicals with its ECOVAXXIN® vaccine family (MS for Mycoplasma synoviae, MG for Mycoplasma gallisepticum). The portfolio also includes Ecomectin® parasiticides and a pipeline of novel vaccines and antibiotics. Products are marketed in over 70 countries through subsidiaries, joint ventures, and distribution partners.

Differentiator

Problem solved

Functional benefit

Brands

• Aivlosin®: Proprietary, patented medication effective against both respiratory and enteric diseases in pigs and poultry. A next generation antibiotic that meets current guidelines for responsible use of antimicrobials. Sold under the tradename Valosin® in some markets.
• Valosin®
• ECOVAXXIN®
• Ecomectin®

Products and services

• Aivlosin®/Valosin® Proprietary patented next-generation macrolide antibiotic containing tylvalosin, effective against both respiratory and enteric diseases in pigs and poultry; meets current guidelines for responsible use of antimicrobials and is available only through veterinary prescription. Sold under the tradename Valosin® in some markets.
• ECOVAXXIN® MS Live attenuated poultry vaccine targeting Mycoplasma synoviae; provides active immunisation of future layer and breeder chickens from four weeks of age to reduce air-sac and foot-pad lesions and egg production losses. Received EU marketing authorisation in December 2025.
• ECOVAXXIN® MG Live poultry vaccine targeting Mycoplasma gallisepticum, responsible for chronic respiratory disease in chickens and infectious sinusitis in turkeys. Received favourable USDA safety assessment in March 2026 with final regulatory submission anticipated in late 2027.
• Ecomectin® Range of parasite treatments including injectables for cattle, sheep and pigs, and premixes for pigs. Products have been shown to be bioequivalent with Ivomec® products by plasma analyses and/or clinical trials.
• Florfenicol (long-acting injectable) Unique, long-acting, injectable animal-only antibiotic intended for use in pigs and administered by veterinary prescription; in late-stage development as part of ECO's commitment to veterinary-only medications.

Quantifiable outcome

• Egg production reduced by 5-10% in layers affected by Mycoplasma synoviae
• +2 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• EU Strategic Distribution PartnerscoreChannel Partner/ Reseller/ Distributor · 1 January 2026Agreements with key strategic distribution partners providing comprehensive coverage across EU's major poultry markets representing over 220 million layer birds annually across the EU's top seven layer-producing countries.
• Moredun Research InstitutecoreStrategic or Co-development Partner · 11 July 2022Partnership for development of poultry red mite vaccine - collaboration on innovative vaccine technology for poultry health.
• Imperial College LondoncoreStrategic or Co-development Partner · 30 June 2022R&D partnership for development of novel solutions for animal health, particularly for pig health technologies.
• PRRSV Vaccine Development PartnerscoreStrategic or Co-development Partner · 15 October 2020Signed two PRRSV vaccine development and licensing deals for novel vaccine approaches to Porcine Reproductive and Respiratory Syndrome Virus.
• Agrinnovation (Yissum LP)coreStrategic or Co-development Partner · 3 December 2018Swine antimicrobial novel formulation development and licensing deal for innovative formulation technologies.
• PharmGatecoreStrategic or Co-development Partner · 1 January 2018Established ECO Pharm Ltd as a joint venture with PharmGate to sell vaccines. PharmGate Animal Health operations established in USA (2010) and Canada (2011) for product distribution.
• Zhejiang ECO-BIOK (China Joint Venture)coreStrategic or Co-development Partner · 1 January 2017Joint venture in China for local production and distribution of animal health products in the world's largest pig and poultry market.
• Research Institutions (MDV, IBDV, NDV, ILTV, IBV)coreStrategic or Co-development PartnerCollaborating with research institutions on development of unique vaccines for Marek's disease virus (MDV), infectious bursal disease virus (IBDV), Newcastle disease virus (NDV), infectious laryngotracheitis virus (ILTV) and novel biopharmaceutical approach for control of infectious bronchitis virus (IBV).
• Contract Manufacturers and CROsminorOthersExtensive use of contract research organisations and third-party manufacturers supporting research and product manufacturing. Completed 36 GMP/GDP/Clinical audits and assessments in FY2025/26 across sites in China, USA, UK, Europe and Latin America.

Scale indicators9 records

Recent moves13 records

Expansion highlights5 records

Broad incumbents

• Elanco Animal Health: Large diversified animal health company with meaningful swine and poultry exposure post-Bayer Animal Health acquisition. Competes with ECO in livestock therapeutics and offers a broad companion-animal franchise alongside production-animal products.
• MSD Animal Health (Merck): Major global animal health player offering vaccines and pharmaceuticals across species, including poultry and swine. ECO's CEO David Hallas previously held P&L responsibility for mid-Europe at MSD Animal Health.
• Zoetis: World's largest animal health company by revenue, offering pharmaceuticals, vaccines, diagnostics and genetic tests across companion and livestock animals. Directly competes with ECO in livestock antibiotics and vaccines, but at vastly greater scale and portfolio breadth.
• Boehringer Ingelheim Animal Health: Global animal health incumbent with a strong swine and poultry portfolio (acquired Merial in 2017). Competes head-on with ECO in livestock therapeutics and vaccines; ECO's Chairman Joachim Hasenmaier previously led this division.

Direct peers

• Virbac: Independent global animal health company focused on pharmaceuticals, vaccines and diagnostics across companion and food-producing animals. Closely comparable to ECO in size, geographic reach, and emphasis on livestock and emerging-market segments.
• Ceva Santé Animale: Large privately held French animal health group with strong swine and poultry vaccine and pharmaceutical portfolios. Direct competitor to ECO in livestock biologicals and antibiotics, particularly in EMEA and Latin America.
• Norbrook: Privately held Northern Ireland-based veterinary pharmaceutical manufacturer with global livestock focus, particularly generics and anti-infectives. Highly comparable mid-sized animal pharma competitor; ECO's Head of Global Marketing previously served as VP of North America and LATAM at Norbrook.
• Dechra Pharmaceuticals: UK-listed specialty veterinary pharmaceuticals company of comparable mid-cap scale, historically focused on companion animals but with growing livestock/food-producing animal exposure. Closest size and listing comparator to ECO on the London market.
• Phibro Animal Health: US-listed animal health and nutrition company with strong focus on livestock (poultry, swine, cattle) pharmaceuticals and vaccines. Highly comparable business mix and customer base to ECO, especially in production-animal therapeutics and biologicals.
• Vetoquinol: Independent French veterinary pharmaceutical company of similar mid-cap scale to ECO, focused on livestock and companion animal therapeutics. Comparable as a privately held mid-sized animal pharma competitor pursuing global distribution in livestock species.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eco-animal-health-ltd.

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ECO Animal Health